Issue 18 - May 3, 2019
Issue 17 - Apr 26, 2019
Issue 16 - Apr 19, 2019
  • Real World Evidence

    How FDA, Pfizer, and Flatiron Health did it

    Approval of Ibrance for men affords a glance at use of real world data

    Real world data played a role in FDA’s recent decision to expand the indications for Pfizer’s drug Ibrance (palbociclib) to include men.

  • NCI advisors approve eight concepts, including three Cancer Moonshot concepts

    The NCI Board of Scientific Advisors approved eight new Requests for Applications, Requests for Proposals, and PAR—a program announcement reviewed in the institute—concepts at a meeting March 25, including three new Cancer Moonshot concepts.

  • Letters to the Editor

    The Cancer Letter is grateful to Mr. Fotopoulos and Mr. Thomson for writing to us.

    Because of incorrect information provided to us, The Cancer Letter reported erroneously that  Dr. Stephen Chagares had performed two robotic mastectomies without a protocol (The Cancer Letter, April 5).

  • In Brief

    • William Cance named interim director of University of Arizona Cancer Center as Andrew Kraft steps down
    • Jefferson, Temple extend due diligence period for negotiations over sale of Fox Chase
    • Dany Habr named chief medical officer at Pfizer Oncology
    • Lisa Kachnic named chair of Columbia Department of Radiation Oncology, chief of Radiation Oncology Service at NY-Presbyterian/Columbia University Irving Medical Center
    • ASCO & The Conquer Cancer  Foundation announce merit awards
    • IMF co-founders Susie and Brian Durie receive honorary doctorate from Vrije Univesiteit Brussel
    • Margo Shoup to join Western Connecticut Health Network as network chair of cancer service line
  • TCCL Logo

  • Clinical Roundup

    • ACP screening guidance calls for two-year interval between mammograms for women at average breast cancer risk
    • Artificial intelligence performs as well as experienced radiologists in detecting prostate cancer
    • Mount Sinai launches clinical trial of new imaging device for head and neck cancer surgeries
    • Cervical cancer subtype rising in some sub-populations
  • Drugs & Targets

    • FDA approves Balversa for urothelial carcinoma with FGFR genetic alterations
    • FDA expands pembrolizumab indication for first-line treatment of NSCLC
    • Aprea Therapeutics receives FDA Fast Track and Orphan Drug designations for APR-246 for MDS
    • Intensity Therapeutics receives Fast Track designation for development of INT230-6 in breast cancer
    • Kitov announces milestone in FameWave acquisition
    • Stanford partners with  Notable and Tempus to make rapid personalized treatment in blood cancer patients
    • OncoSec anounces collaboration with Duke to study TAVO + plasmid DNA vaccines in breast cancer
    • Roswell Park selects Circuit Clinical as collaborator for CIMAvax clinical trial